Business
Capital Markets Day and investor conferences
Oxford Biomedica PLC has announced its Capital Markets Day will be held on June 2, 2026, at the London Stock Exchange Group headquarters. The company will also participate in several upcoming investor conferences, including the UBS European Healthcare Conference on March 3-4, 2026, the Berenberg UK Corporate Conference on March 17-19, 2026, the Needham Virtual Healthcare Conference on April 13-16, 2026, and the Berenberg Midsummer Midcaps Conference on June 4-5, 2026. Additionally, Oxford Biomedica will report its preliminary results for the twelve months ended December 31, 2025, on March 26, 2026, followed by a virtual analyst briefing. Disclaimer*
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n\n \n \nOXB announces date for Capital Markets Day and participation in upcoming investor conferences\n \nOxford, UK - 3 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces the date of its Capital Markets Day and participation at upcoming investor conferences.\nCapital Markets Day\nOXB will hold its Capital Markets Day at the London Stock Exchange Group (LSEG) headquarters on 2 June 2026. Further details, including the agenda and registration information, will be provided in due course.\nUpcoming Investor Conferences\nUBS European Healthcare Conference \nDate: 3 - 4 March 2026\nLocation: London, UK\nBerenberg UK Corporate Conference \nDate: 17- 19 March 2026\nLocation: Watford, UK\n25th Annual Needham Virtual Healthcare Conference\nDate: 13 - 16 April 2026\nLocation: Virtual\nBerenberg Midsummer Midcaps Conference\nDate: 4 - 5 June 2026\nLocation: Ascot, UK\nInvestors attending any of the above conferences who would like to meet with OXB are welcome to contact the Company's IR team via [email protected].\nLive webcasts and recordings of presentations, where available, will be accessible under 'Results, Reports, Presentations & Webcasts' in the Investor Relations section of OXB's website at www.oxb.com.\nFY 2025 Preliminary Results\nAs previously announced, OXB will report its preliminary results for the twelve months ended 31 December 2025 on 26 March 2026. OXB's management team, led by Dr. Frank Mathias, Chief Executive Officer, Dr. Lucy Crabtree, Chief Financial Officer, and Dr. Sébastien Ribault, Chief Business Officer, will host a virtual analyst briefing at 13:00 GMT / 08:00 ET. To register, please contact [email protected].\nFor details of other upcoming financial events, please refer to the Company's investor calendar at https://oxb.com/investor-events/.\n \n-Ends-\n \nEnquiries: \n \nOXB:\nT: +44 (0) 1865 509 737 / E: [email protected]\nSophia Bolhassan, Head of Investor Relations\nICR Healthcare:\nT: +44 (0)20 3709 5700 / E: [email protected]\nMary-Jane Elliott / Sarah Elton-Farr / Davide Salvi\n \n \nAbout OXB\n \nOXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to en...